InnoCare Pharma has filed a patent for heterocyclic compounds that act as immunomodulators. The compounds, represented by general formula (I), can be used to treat and prevent tumors, inflammations, and immune diseases. The patent also covers methods for preparing these compounds. GlobalData’s report on InnoCare Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on InnoCare Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. InnoCare Pharma's grant share as of September 2023 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230271933A1) describes a compound represented by a general formula (I), along with its various derivatives and isomers. The compound can be a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer.
The compound described in the patent has a specific structure, with ring A being a monocyclic heterocycle containing one nitrogen atom or a fused-, bridged-, or spiro-bicyclic heterocycle. The patent also mentions that R4, an attached group, can be D, halogen, oxo, —CF3, or C1-6alkyl.
Additionally, the patent describes another variation of the compound, where ring A is a monocyclic heterocycle containing two nitrogen atoms or a fused-, bridged-, or spiro-bicyclic heterocycle. In this case, R4 is attached to the second nitrogen atom and can be C1-6alkyl, C3-6cycloalkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —S(O)2C1-6alkyl, —S(O)2C3-6cycloalkyl, phenyl, or a 5- or 6-membered heteroaryl containing nitrogen, oxygen, and/or sulfur. The patent also mentions that one or more hydrogens of the attached groups can be substituted with D, halogen, cyano, C1-2alkyl, or fluoroC1-2alkyl.
The patent further describes variations of the compound where R2 is hydrogen and R3 is cyano, C1-6alkyl, or C3-6cycloalkyl. It also mentions a variation where both R2 and R3 are methyl. Another variation is described where R2 and R3, along with the carbon atoms attached to them, form a cycloalkane with 3 to 6 carbon atoms.
The patent also includes claims related to pharmaceutical compositions containing the compound, either alone or in combination with other drugs. These compositions can be used for treating or preventing diseases mediated by specific proteins or molecules, such as Aiolos, Ikaros, Helios, CK1a, GSPT1, IL-2, IL-6, TNFa, IFN?, VEGF, and others. The diseases mentioned include hematological tumors, solid tumors, autoimmune diseases, inflammations, neurodegenerative diseases, and skin diseases, among others.
In summary, the patent describes a compound and its various derivatives and isomers, along with their potential use in pharmaceutical compositions for the treatment or prevention of various diseases. The compound has a specific structure and can be modified with different attached groups to enhance its therapeutic properties.
To know more about GlobalData’s detailed insights on InnoCare Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
